WINTON GROUP Ltd Acquires Shares of 2,569 PROCEPT BioRobotics Co. (NASDAQ:PRCT)

WINTON GROUP Ltd bought a new position in PROCEPT BioRobotics Co. (NASDAQ:PRCT) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor bought 2,569 shares of the company’s stock, valued at approximately $207,000.

Other institutional investors also recently modified their holdings of the company. Raleigh Capital Management Inc. purchased a new stake in PROCEPT BioRobotics in the fourth quarter worth about $32,000. Signaturefd LLC grew its stake in shares of PROCEPT BioRobotics by 26.7% in the 4th quarter. Signaturefd LLC now owns 689 shares of the company’s stock worth $55,000 after buying an additional 145 shares during the last quarter. IFP Advisors Inc bought a new position in PROCEPT BioRobotics during the 4th quarter valued at approximately $58,000. Wilmington Savings Fund Society FSB purchased a new position in PROCEPT BioRobotics during the third quarter valued at $64,000. Finally, Arcadia Investment Management Corp MI bought a new position in PROCEPT BioRobotics in the 4th quarter worth about $64,000. 89.46% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Wells Fargo & Company reaffirmed an “overweight” rating and issued a $112.00 price objective on shares of PROCEPT BioRobotics in a research report on Tuesday, December 3rd. Morgan Stanley reduced their price objective on PROCEPT BioRobotics from $105.00 to $95.00 and set an “overweight” rating for the company in a report on Wednesday, February 26th. Finally, Truist Financial restated a “buy” rating and set a $90.00 target price (down previously from $105.00) on shares of PROCEPT BioRobotics in a research note on Wednesday, February 26th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, PROCEPT BioRobotics has a consensus rating of “Moderate Buy” and a consensus price target of $94.29.

PROCEPT BioRobotics Trading Down 3.0 %

Shares of NASDAQ:PRCT opened at $58.26 on Tuesday. The stock’s 50-day simple moving average is $64.98 and its two-hundred day simple moving average is $77.66. The company has a debt-to-equity ratio of 0.21, a quick ratio of 5.07 and a current ratio of 6.02. The stock has a market capitalization of $3.19 billion, a price-to-earnings ratio of -29.88 and a beta of 1.05. PROCEPT BioRobotics Co. has a 52-week low of $45.56 and a 52-week high of $103.81.

PROCEPT BioRobotics (NASDAQ:PRCT) last issued its quarterly earnings data on Tuesday, February 25th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). PROCEPT BioRobotics had a negative net margin of 50.07% and a negative return on equity of 38.57%. The business had revenue of $68.24 million for the quarter, compared to the consensus estimate of $66.79 million. Analysts expect that PROCEPT BioRobotics Co. will post -1.75 EPS for the current year.

Insiders Place Their Bets

In other PROCEPT BioRobotics news, CEO Reza Zadno sold 5,475 shares of the company’s stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total value of $312,403.50. Following the completion of the transaction, the chief executive officer now directly owns 173,070 shares in the company, valued at $9,875,374.20. This represents a 3.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Kevin Waters sold 733 shares of the stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total transaction of $41,824.98. Following the completion of the sale, the chief financial officer now directly owns 107,991 shares of the company’s stock, valued at approximately $6,161,966.46. This trade represents a 0.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 6,455 shares of company stock worth $368,322 over the last quarter. 17.40% of the stock is currently owned by corporate insiders.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).